Trial Profile
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Mezigdomide (Primary) ; Selinexor (Primary) ; Belantamab mafodotin; Bortezomib; Carfilzomib; Clarithromycin; Daratumumab; Dexamethasone; Elotuzumab; Ixazomib; Lenalidomide; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms STOMP
- Sponsors Karyopharm Therapeutics
- 30 Oct 2023 According to Karyopharm Therapeutics media release, under the terms of the agreement with Bristol Myers Squibb, Karyopharm will sponsor the trial as a new arm of Karyopharm's Phase 1b/2 STOMP trial and Bristol Myers Squibb will supply the study's clinical drug mezigdomide.
- 26 Sep 2023 According to Karyopharm Therapeutics media release, data from this study will be presented at the 2023 International Myeloma Society (IMS) Annual Meeting, being held September 27-30 in Athens, Greece.
- 01 Sep 2023 Results assessing efficacy and safety of selinexor-based triplets in a subset of patients from clinical trials: STOMP and BOSTON treated previously with alphaCD38 mAbs published in the Clinical Lymphoma, Myeloma & Leukemia